Cross River Announces Update to Non-Brokered Private Placement
Reuters 11/11 21:44
NKGen Biotech Announced The Dosing Of The First Patient In Its Phase 1/2a Trial Evaluating SNK01, A Cryopreserved Autologous, Non-Genetically Modified NK Cell Therapy Product With Enhanced Cytotoxicity And Activating Receptor Expression
NKGen Biotech, Inc. 0.00% Post
NKGen Biotech, Inc. NKGN | 0.00 |
NKGen Biotech's autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease ("AD") in its Phase 1 dose-escalation safety trial.
SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD.
Initial patient in this Phase 1/2a trial received 6 billion cells, 50% more than the maximum dosing from the Phase 1 trial.
Recommend
SoFi Technologies’ Crypto Trading Launch Could Be a Game Changer for SOFI
Simply Wall St 11/11 23:35Natera (NTRA) Is Up 5.2% After Raising 2025 Revenue Guidance and Expanding Women’s Health Portfolio
Simply Wall St 12/11 06:18Don't Copy That Code! The New 'ClickFix' Cyber Attack Can Infect Your Computer In Seconds
Benzinga News 12/11 06:11Metsera (MTSR): Assessing Valuation After This Year’s 167% Stock Surge
Simply Wall St 12/11 06:19Reported Earlier, Centessa Pharmaceuticals Prices $250M Public Offering Of 11,627,907 American Depositary Shares At $21.50 Per Share
Benzinga News 12/11 07:14'GM Wants Parts Makers To Pull Supply Chains From China' - Reuters Exclusive
Benzinga News 12/11 07:28Euro zone bonds steady; focus on US shutdown vote, jobs
Reuters 12/11 07:34
